Shanghai RAAS Blood Products saw no growth in patent filings and highest growth of 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Shanghai RAAS Blood Products’s patent filings and grants. Buy the databook here.
Shanghai RAAS Blood Products has been focused on protecting inventions in China(CN) with two publications in Q2 2024
The China(CN) Patent Office dominates the patent filings and grants with nearly 100% filings and 100% grants. The China(CN) patent Office are among the top ten patent offices where Shanghai RAAS Blood Products is filings its patents. Among the top granted patent authorities, Shanghai RAAS Blood Products has 100% of its grants in China(CN).
University of Valencia and Scripps Research Institute could be the strongest competitors for Shanghai RAAS Blood Products
Shanghai RAAS Blood Products stands in second position with respect to its patent publications among its competitors.
Patents related to climate change lead Shanghai RAAS Blood Products's portfolio
Shanghai RAAS Blood Products has the highest number of patents in climate change. For climate change no patents were filed and 100% of patents were granted in Q2 2024.
For comprehensive analysis of Shanghai RAAS Blood Products's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.